Simcere Pharmaceutical of Nanjing paid 111 million RMB ($14.8 million) for a 51% stake in Boda Pharmaceutical, a company that markets a rival to Simcere’s best-selling drug, Bicun. Bicun, an injected edaravone, is a neuroprotective drug, administered following a stroke.  Boda, which makes the only other injected edaravone available in China, has not released revenue figures, but Simcere said the company was “fast-growing.” More details...

Stock Symbol: (NYSE:SCR)